A new clinical validation study, published in the Journal of Clinical Oncology CCI, found that Medial EarlySign’s artificial intelligence tool flagged about 8 percent of patients in a large trial group that were later diagnosed with cancer or precancerous lesions.
“The implementation of machine-learning based algorithms to risk stratify populations at risk is commonly feared by many clinicians...
